((自动化翻译由路透提供，请见免责声明 ))
1月2日 - ** H.C. Wainwright经纪公司开始对Corvus Pharmaceuticals 进行评级，给予 "买入 "评级，目标价为11美元。
** 与该股周二收盘价相比，PT上涨了2倍
** CRVS正在测试其实验性药物soquelitinib，这是一种首创的ITK特异性抑制剂，用于治疗罕见癌症和湿疹，湿疹是一种自身免疫性疾病，会引起皮肤发红发痒。
** 索克替尼（Soquelitinib）的作用原理是阻断对 T 细胞（一种白细胞）活化至关重要的 ITK 酶，降低 T 细胞活性并控制免疫反应。
** 经纪公司称，这种药物 "在牛皮癣、炎症性肠病和过敏性哮喘等其他多种疾病中也有潜力"。
** H.C. Wainwright 表示，如果该药物的后期研究取得成功，它将于 2027 年在美国获得批准。
** 券商预测 Soquelitinib 到 2034 年的总收入将达到 8.01 亿美元
** 2024 年股价上涨约 204
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.